home > Which solutions ? > Allergy immunotherapy


The only treatment of the cause of respiratory allergy, allergy immunotherapy is a way of “desensitising” the immune system that can specifically target house dust mite allergy.


Is immunotherapy for me?

Allergy immunotherapy is designed for patients (from the age of 5) suffering from a severe respiratory allergy for whom symptomatic treatments have proved insufficient.



Scientifically recognised effectiveness

It has been shown that allergy immunotherapy is capable of significantly reducing both the symptoms of allergy and recourse to symptomatic treatments. In addition, its effects are long-term and it can even play a role in preventing the development of other allergies or asthma1. By acting directly on the cause, only allergy immunotherapy is therefore capable of offering lasting treatment for allergic conditions.


How does it work?



Allergy immunotherapy consists of administering gradually increasing doses of allergens to the patient. In response, the body’s immunes system alters production of certain antibodies (immunoglobulin) and proteins (interleukins), which reduces hyper-reactivity of the immune system and the resulting inflammation.


Treatment can be administered in different ways:

as well as subcutaneous delivery (injections into the arm), treatment may also be administered sublingually (drops or tablets placed under the tongue).
Allergy immunotherapy treatment can only be prescribed by an allergy specialist.



When to start allergy immunotherapy?

In the case of seasonal allergies such as an allergy to pollen, treatment can only be taken for a few months during the year. It begins a few months before, and continues throughout, the pollen season. Treatment is resumed the following year and follows the same protocol. In the case of perennial allergies like house dust mite or animal hair allergies, treatment continues throughout the year.


[1] Jacobsen L. et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug;62(8):943-8.